Vaxart Stock Shoots Higher After Its Oral Vaccine Boosts Immune Response In Previously Vaccinated Subject


Vaxart Inc's VXRT has disclosed data from a 12-subject Phase 1b blinded study evaluating the ability of its oral norovirus vaccine to boost immunogenicity. 

  • Study participants were initially vaccinated with Vaxart's oral norovirus vaccine in late 2019 and were vaccinated again between February and April 2021.  
  • All seven previously immunized participants with the oral norovirus vaccine-elicited similar immune responses to norovirus as the five subjects who did not receive an initial oral vaccine dose.  
  • Serum antibody blocking titer 50, a surrogate neutralizing antibody measurement, increased in both previously vaccinated and unvaccinated subjects by similar amounts. 
  • Antibody secreting B cell responses to norovirus VP1 measured seven days post-boost were no different from those in subjects receiving the vaccine for the first time. 
  • Serum IgG and IgA antibody responses were significantly elevated 29 days post-boost immunization, with no difference in titer between vaccinated and unvaccinated subjects.
  • Price Action: VXRT shares are 5.06% at $8.63 during the market session on the last check Thursday.
  • Image by Wilfried Pohnke from Pixabay
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLong IdeasNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!